REVLIMID® (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells). REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.
The most prescribed for newly diagnosed multiple myeloma therapy*
*Claims data 07/2017-06/2020. Source: IntrinsiQ Data © 2020. IntrinsiQ Specialty Solutions, Inc.
How REVLIMID works
REVLIMID works in multiple aspects to ﬁght multiple myeloma. REVLIMID is an immune-modulating therapy with proven anti-myeloma eﬀects. REVLIMID is an oral therapy that was shown to work in 3 ways in animal models and in vitro†:
Helps your immune system recognize and destroy myeloma cells.
Targets and kills myeloma cells.
Helps prevent new myeloma cell growth by starving them of blood.
REVLIMID is used in several FDA-approved therapy combinations to treat multiple myeloma.
The FDA has approved several combination therapies with REVLIMID for the treatment of multiple myeloma.
Your doctor may discuss these other treatment options and the associated risks and benefits with you.
A clinical trial proved REVLIMID with dexamathasone was effective for newly diagnosed patients.
A clinical study that enrolled 1623 patients looked at the safety and effectiveness of REVLIMID with dexamethasone compared with a combination of melphalan, prednisone, and thalidomide as a treatment for newly diagnosed patients with multiple myeloma who had not received a stem cell transplant.
The primary goal of the study was to evaluate:
- Progression-free survival (PFS)—how long patients lived without the disease getting worse
The secondary goals of the study were:
- Overall survival (OS)—the length of time patients lived since the start of treatment
- Overall response rate (ORR)—how patients responded to treatment overall
Patients were divided into 3 groups:
- The first group took REVLIMID with dexamethasone continuously‡
- The second group took REVLIMID with dexamethasone for up to 18 months
- The third group took a combination of the drugs melphalan, prednisone, and thalidomide for up to 18 months
‡Until the multiple myeloma got worse or patients experienced intolerable side effects.
Patients who took REVLIMID with dexamethasone
Longer progression-free survival (PFS)
Compared with patients who took REVLIMID with dexamethasone for only 18 months, or who took a combination of melphalan, prednisone, and thalidomide.
Longer overall survival (OS)
Compared with patients who took a combination of melphalan, prednisone, and thalidomide.
Higher overall response rate (ORR)
Patients who took REVLIMID and dexamethasone continuously had a 75% response rate compared to 73% of patients who took REVLIMID and dexamethasone for only 18 months and 62% of patients who took the combination of melphalan, prednisone, and thalidomide.
The most common side effects of REVLIMID (≥20%) include: diarrhea, rash, nausea, constipation, tiredness or weakness, fever, itching, swelling of your arms, hands, legs, feet, and skin, sleep problems (insomnia), headache,§ muscle cramps or spasms, shortness of breath, cough, sore throat, and other symptoms of a cold, upper respiratory tract infection or bronchitis, inflammation of the stomach and intestine (“stomach flu”), nose bleed,§ shaking or trembling (tremor), joint aches,§ and pain in your back or stomach area (abdomen).
§Occurred in (≥5%) of patients.